<DOC>
	<DOCNO>NCT00255255</DOCNO>
	<brief_summary>This study confirm safety Symbicort® Turbuhaler® 160/4.5 µg 1 , 2 4 inhalation b.i.d . 52 week treatment period asthmatic patient treat IGCS long act β2-agonist ( LABA ) and/or anti-asthmatic drug .</brief_summary>
	<brief_title>Safety &amp; Efficacy Symbicort® Turbuhaler® ( 1 , 2 , 4 x 160/4.5 µg Twice Daily ) Japanese Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Diagnosis asthma document history least 6 month duration prior Visit 1 Prescribed daily use IGCS ≥12 week prior Visit 1 Prescribed daily use least one following : Theophylline , long act β2agonist ( LABA ) , antiasthmatic drug ( leucotrine antagonist , inhaled anticholinergic , Th2 cytokine inhibitor ) least 4 week prior Visit 1 constant dose Any significant disease disorder may jeopardize safety patient Respiratory infection , judge investigator ( ) infection affect asthma , within 4 week prior Visit 1 Treatment oral , parenteral rectal GCS within 4 week prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Asthma</keyword>
</DOC>